schliessen

Filtern

 

Bibliotheken

Cover Image

Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection

Toxoplasma gondii rhoptry protein 18 (ROP18) and microneme protein 8 (MIC8) are important invasion factors that mediate parasite multiplication. The main objective of this study was to determine the immunogenicity and efficacy by virus-like particle (VLP) vaccines of T. gondii ROP18 VLPs and MIC8 VL... Full description

Journal Title: Vaccine 2018-09-11, Vol.36 (38), p.5692-5700
Main Author: Lee, Su-Hwa
Other Authors: Kang, Hae-Ji , Lee, Dong-Hun , Kang, Sang-Moo , Quan, Fu-Shi
Format: Electronic Article Electronic Article
Language: English
Subjects:
Animals
Antibodies, Protozoan - blood
Antigens
Apoptosis - immunology
Cell Adhesion Molecules - immunology
Cell Line
Female
Health aspects
Immunoglobulin A - blood
Immunoglobulin G - blood
Interferon-gamma - blood
Interleukin-6 - blood
Medical colleges
Mice
Mice, Inbred BALB C
Microneme protein 8
Protein-Serine-Threonine Kinases - immunology
Protozoan Proteins - immunology
Protozoan Vaccines - immunology
Research institutes
Rhoptry protein 18
Sf9 Cells
Spodoptera
Synergistic effects
T cells
Toxoplasma gondii
Toxoplasmosis, Animal - immunology
Toxoplasmosis, Animal - prevention & control
Vaccination
Vaccine
Vaccines
Vaccines, Virus-Like Particle - immunology
Virus-like particles
Quelle: Alma/SFX Local Collection
Publisher: Netherlands: Elsevier Ltd
ID: ISSN: 0264-410X
Link: https://www.ncbi.nlm.nih.gov/pubmed/30107996
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_2088746413
title: Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection
format: Article
creator:
  • Lee, Su-Hwa
  • Kang, Hae-Ji
  • Lee, Dong-Hun
  • Kang, Sang-Moo
  • Quan, Fu-Shi
subjects:
  • Animals
  • Antibodies, Protozoan - blood
  • Antigens
  • Apoptosis - immunology
  • Cell Adhesion Molecules - immunology
  • Cell Line
  • Female
  • Health aspects
  • Immunoglobulin A - blood
  • Immunoglobulin G - blood
  • Interferon-gamma - blood
  • Interleukin-6 - blood
  • Medical colleges
  • Mice
  • Mice, Inbred BALB C
  • Microneme protein 8
  • Protein-Serine-Threonine Kinases - immunology
  • Protozoan Proteins - immunology
  • Protozoan Vaccines - immunology
  • Research institutes
  • Rhoptry protein 18
  • Sf9 Cells
  • Spodoptera
  • Synergistic effects
  • T cells
  • Toxoplasma gondii
  • Toxoplasmosis, Animal - immunology
  • Toxoplasmosis, Animal - prevention & control
  • Vaccination
  • Vaccine
  • Vaccines
  • Vaccines, Virus-Like Particle - immunology
  • Virus-like particles
ispartof: Vaccine, 2018-09-11, Vol.36 (38), p.5692-5700
description: Toxoplasma gondii rhoptry protein 18 (ROP18) and microneme protein 8 (MIC8) are important invasion factors that mediate parasite multiplication. The main objective of this study was to determine the immunogenicity and efficacy by virus-like particle (VLP) vaccines of T. gondii ROP18 VLPs and MIC8 VLPs in combination or individuals. Mice were intranasally immunized with single ROP18 VLPs or MIC8 VLPs, or a combination of ROP18 VLPs and MIC8 VLPs followed by challenge with T. gondii tachyzoites (GT1) through intraperitoneal injection or challenge with T. gondii (ME49) through oral infection. Vaccination with a combination of ROP18 VLPs and MIC8 VLPs resulted in more potent effects on inducing parasite neutralizing activity, memory T cell response, and reducing parasite burden compared to single VLP vaccination. Lower levels of inflammatory cytokines (IFN-γ, IL-6) and apoptosis responses were observed with VLP vaccine combination after challenge. These results suggest that VLP vaccines presenting both T. gondii ROP18 and MIC8 antigens confer enhanced protection compared to a single VLPs vaccine, and VLP platforms could be developed as potential vaccines against toxoplasmosis.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0264-410X
fulltext: fulltext
issn:
  • 0264-410X
  • 1873-2518
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.620357
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_2088746413
sourceformatXML
sourcesystemPC
galeidA552520431
sourcerecordidA552520431
originalsourceidFETCH-LOGICAL-c396t-a088fa45304ab248df9f740966df57bfc1e11174c78c0231c0a3dff57e791a4a3
addsrcrecordideNqFUU1v1DAQtRCIbgs_AeQjlwRP7HyJA6oqoEiVuBTEzfI64-0siRPs7Kq98dNxlKUHLpVHsuWZ92beG8begMhBQPV-nx-NteQxLwQ0uUgB1TO2gaaWWVFC85xtRFGpTIH4ecbOY9wLIUoJ7Ut2JgWIum2rDfvzg8IhZj39Qj6ZMJPtkZ-YI8f7KWCM5Hf8drwfp97EwfDd6DsiHu7GaQ4PfArjjOQ5NNz4jg9kw-hxwMdEs7yO1CFHf2e8xW5N2ZlG_4q9cKaP-Pp0X7Dvnz_dXl1nN9--fL26vMmsbKs5M6JpnFGlFMpsC9V0rnW1Em1Vda6st84CAkCtbN1YUUiwwsjOpRTWLRhl5AV7t_Km1r8PGGc9ULTY98bjeIi6SA1qVSmQqTRfS3emR03ejXMwNp0Ok7ikzVH6vyzLoiyEkpAA5QpIymMM6PQUaDDhQYPQy7b0Xp881cu2tEgBVcK9Pc102A7YPaL-rScVfPiP2NJsFtvSRNQ_Sf9xRWPy9UgYdLSEi_8Ukvm6G-kJhr8qPL8H
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid2088746413
display
typearticle
titleVirus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection
sourceAlma/SFX Local Collection
creatorLee, Su-Hwa ; Kang, Hae-Ji ; Lee, Dong-Hun ; Kang, Sang-Moo ; Quan, Fu-Shi
creatorcontribLee, Su-Hwa ; Kang, Hae-Ji ; Lee, Dong-Hun ; Kang, Sang-Moo ; Quan, Fu-Shi
descriptionToxoplasma gondii rhoptry protein 18 (ROP18) and microneme protein 8 (MIC8) are important invasion factors that mediate parasite multiplication. The main objective of this study was to determine the immunogenicity and efficacy by virus-like particle (VLP) vaccines of T. gondii ROP18 VLPs and MIC8 VLPs in combination or individuals. Mice were intranasally immunized with single ROP18 VLPs or MIC8 VLPs, or a combination of ROP18 VLPs and MIC8 VLPs followed by challenge with T. gondii tachyzoites (GT1) through intraperitoneal injection or challenge with T. gondii (ME49) through oral infection. Vaccination with a combination of ROP18 VLPs and MIC8 VLPs resulted in more potent effects on inducing parasite neutralizing activity, memory T cell response, and reducing parasite burden compared to single VLP vaccination. Lower levels of inflammatory cytokines (IFN-γ, IL-6) and apoptosis responses were observed with VLP vaccine combination after challenge. These results suggest that VLP vaccines presenting both T. gondii ROP18 and MIC8 antigens confer enhanced protection compared to a single VLPs vaccine, and VLP platforms could be developed as potential vaccines against toxoplasmosis.
identifier
0ISSN: 0264-410X
1EISSN: 1873-2518
2DOI: 10.1016/j.vaccine.2018.08.016
3PMID: 30107996
languageeng
publisherNetherlands: Elsevier Ltd
subjectAnimals ; Antibodies, Protozoan - blood ; Antigens ; Apoptosis - immunology ; Cell Adhesion Molecules - immunology ; Cell Line ; Female ; Health aspects ; Immunoglobulin A - blood ; Immunoglobulin G - blood ; Interferon-gamma - blood ; Interleukin-6 - blood ; Medical colleges ; Mice ; Mice, Inbred BALB C ; Microneme protein 8 ; Protein-Serine-Threonine Kinases - immunology ; Protozoan Proteins - immunology ; Protozoan Vaccines - immunology ; Research institutes ; Rhoptry protein 18 ; Sf9 Cells ; Spodoptera ; Synergistic effects ; T cells ; Toxoplasma gondii ; Toxoplasmosis, Animal - immunology ; Toxoplasmosis, Animal - prevention & control ; Vaccination ; Vaccine ; Vaccines ; Vaccines, Virus-Like Particle - immunology ; Virus-like particles
ispartofVaccine, 2018-09-11, Vol.36 (38), p.5692-5700
rights
02018 Elsevier Ltd
1Copyright © 2018 Elsevier Ltd. All rights reserved.
2COPYRIGHT 2018 Elsevier B.V.
lds50peer_reviewed
citedbyFETCH-LOGICAL-c396t-a088fa45304ab248df9f740966df57bfc1e11174c78c0231c0a3dff57e791a4a3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30107996$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Lee, Su-Hwa
1Kang, Hae-Ji
2Lee, Dong-Hun
3Kang, Sang-Moo
4Quan, Fu-Shi
title
0Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection
1Vaccine
addtitleVaccine
descriptionToxoplasma gondii rhoptry protein 18 (ROP18) and microneme protein 8 (MIC8) are important invasion factors that mediate parasite multiplication. The main objective of this study was to determine the immunogenicity and efficacy by virus-like particle (VLP) vaccines of T. gondii ROP18 VLPs and MIC8 VLPs in combination or individuals. Mice were intranasally immunized with single ROP18 VLPs or MIC8 VLPs, or a combination of ROP18 VLPs and MIC8 VLPs followed by challenge with T. gondii tachyzoites (GT1) through intraperitoneal injection or challenge with T. gondii (ME49) through oral infection. Vaccination with a combination of ROP18 VLPs and MIC8 VLPs resulted in more potent effects on inducing parasite neutralizing activity, memory T cell response, and reducing parasite burden compared to single VLP vaccination. Lower levels of inflammatory cytokines (IFN-γ, IL-6) and apoptosis responses were observed with VLP vaccine combination after challenge. These results suggest that VLP vaccines presenting both T. gondii ROP18 and MIC8 antigens confer enhanced protection compared to a single VLPs vaccine, and VLP platforms could be developed as potential vaccines against toxoplasmosis.
subject
0Animals
1Antibodies, Protozoan - blood
2Antigens
3Apoptosis - immunology
4Cell Adhesion Molecules - immunology
5Cell Line
6Female
7Health aspects
8Immunoglobulin A - blood
9Immunoglobulin G - blood
10Interferon-gamma - blood
11Interleukin-6 - blood
12Medical colleges
13Mice
14Mice, Inbred BALB C
15Microneme protein 8
16Protein-Serine-Threonine Kinases - immunology
17Protozoan Proteins - immunology
18Protozoan Vaccines - immunology
19Research institutes
20Rhoptry protein 18
21Sf9 Cells
22Spodoptera
23Synergistic effects
24T cells
25Toxoplasma gondii
26Toxoplasmosis, Animal - immunology
27Toxoplasmosis, Animal - prevention & control
28Vaccination
29Vaccine
30Vaccines
31Vaccines, Virus-Like Particle - immunology
32Virus-like particles
issn
00264-410X
11873-2518
fulltexttrue
rsrctypearticle
creationdate2018
recordtypearticle
recordideNqFUU1v1DAQtRCIbgs_AeQjlwRP7HyJA6oqoEiVuBTEzfI64-0siRPs7Kq98dNxlKUHLpVHsuWZ92beG8begMhBQPV-nx-NteQxLwQ0uUgB1TO2gaaWWVFC85xtRFGpTIH4ecbOY9wLIUoJ7Ut2JgWIum2rDfvzg8IhZj39Qj6ZMJPtkZ-YI8f7KWCM5Hf8drwfp97EwfDd6DsiHu7GaQ4PfArjjOQ5NNz4jg9kw-hxwMdEs7yO1CFHf2e8xW5N2ZlG_4q9cKaP-Pp0X7Dvnz_dXl1nN9--fL26vMmsbKs5M6JpnFGlFMpsC9V0rnW1Em1Vda6st84CAkCtbN1YUUiwwsjOpRTWLRhl5AV7t_Km1r8PGGc9ULTY98bjeIi6SA1qVSmQqTRfS3emR03ejXMwNp0Ok7ikzVH6vyzLoiyEkpAA5QpIymMM6PQUaDDhQYPQy7b0Xp881cu2tEgBVcK9Pc102A7YPaL-rScVfPiP2NJsFtvSRNQ_Sf9xRWPy9UgYdLSEi_8Ukvm6G-kJhr8qPL8H
startdate20180911
enddate20180911
creator
0Lee, Su-Hwa
1Kang, Hae-Ji
2Lee, Dong-Hun
3Kang, Sang-Moo
4Quan, Fu-Shi
general
0Elsevier Ltd
1Elsevier B.V
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
97X8
sort
creationdate20180911
titleVirus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection
authorLee, Su-Hwa ; Kang, Hae-Ji ; Lee, Dong-Hun ; Kang, Sang-Moo ; Quan, Fu-Shi
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c396t-a088fa45304ab248df9f740966df57bfc1e11174c78c0231c0a3dff57e791a4a3
rsrctypearticles
prefilterarticles
languageeng
creationdate2018
topic
0Animals
1Antibodies, Protozoan - blood
2Antigens
3Apoptosis - immunology
4Cell Adhesion Molecules - immunology
5Cell Line
6Female
7Health aspects
8Immunoglobulin A - blood
9Immunoglobulin G - blood
10Interferon-gamma - blood
11Interleukin-6 - blood
12Medical colleges
13Mice
14Mice, Inbred BALB C
15Microneme protein 8
16Protein-Serine-Threonine Kinases - immunology
17Protozoan Proteins - immunology
18Protozoan Vaccines - immunology
19Research institutes
20Rhoptry protein 18
21Sf9 Cells
22Spodoptera
23Synergistic effects
24T cells
25Toxoplasma gondii
26Toxoplasmosis, Animal - immunology
27Toxoplasmosis, Animal - prevention & control
28Vaccination
29Vaccine
30Vaccines
31Vaccines, Virus-Like Particle - immunology
32Virus-like particles
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Lee, Su-Hwa
1Kang, Hae-Ji
2Lee, Dong-Hun
3Kang, Sang-Moo
4Quan, Fu-Shi
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8MEDLINE - Academic
jtitleVaccine
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Lee, Su-Hwa
1Kang, Hae-Ji
2Lee, Dong-Hun
3Kang, Sang-Moo
4Quan, Fu-Shi
formatjournal
genrearticle
ristypeJOUR
atitleVirus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection
jtitleVaccine
addtitleVaccine
date2018-09-11
risdate2018
volume36
issue38
spage5692
epage5700
pages5692-5700
issn0264-410X
eissn1873-2518
abstractToxoplasma gondii rhoptry protein 18 (ROP18) and microneme protein 8 (MIC8) are important invasion factors that mediate parasite multiplication. The main objective of this study was to determine the immunogenicity and efficacy by virus-like particle (VLP) vaccines of T. gondii ROP18 VLPs and MIC8 VLPs in combination or individuals. Mice were intranasally immunized with single ROP18 VLPs or MIC8 VLPs, or a combination of ROP18 VLPs and MIC8 VLPs followed by challenge with T. gondii tachyzoites (GT1) through intraperitoneal injection or challenge with T. gondii (ME49) through oral infection. Vaccination with a combination of ROP18 VLPs and MIC8 VLPs resulted in more potent effects on inducing parasite neutralizing activity, memory T cell response, and reducing parasite burden compared to single VLP vaccination. Lower levels of inflammatory cytokines (IFN-γ, IL-6) and apoptosis responses were observed with VLP vaccine combination after challenge. These results suggest that VLP vaccines presenting both T. gondii ROP18 and MIC8 antigens confer enhanced protection compared to a single VLPs vaccine, and VLP platforms could be developed as potential vaccines against toxoplasmosis.
copNetherlands
pubElsevier Ltd
pmid30107996
doi10.1016/j.vaccine.2018.08.016